Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ulcerative colitis: responding to the challenges.

Jean-Paul Achkar1

  • 1Department of Gastroenterology and Hepatology, Cleveland Clinic, OH 44195, USA. achkarj@ccf.org

Cleveland Clinic Journal of Medicine
|September 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neonatal and Pregnancy Outcomes in Pregnant Adults With Pediatric-Onset Crohn's Disease.

Gastro hep advances·2026
Same author

Outcomes of Percutaneous Coronary Intervention in Patients with Inflammatory Bowel Disease.

Journal of clinical medicine·2026
Same author

Mechanisms and Management of Ileus.

The American journal of gastroenterology·2025
Same author

Signaling in the Gastroenterology Fellowship Match: A Primer for Applicants and Programs.

Digestive diseases and sciences·2025
Same author

Optimal Sequencing in Same-Day Bidirectional Endoscopy: A Tertiary US Healthcare Center Experience.

Digestive diseases and sciences·2025
Same author

Quality indicators for colonoscopy.

Gastrointestinal endoscopy·2024
Same journal

A 20-year-old woman with a 9-year history of shortness of breath.

Cleveland Clinic journal of medicine·2026
Same journal

A 70-year-old man with lower-extremity weakness and falls.

Cleveland Clinic journal of medicine·2026
Same journal

Treatment-refractory hypothyroidism: Don't just increase the dose.

Cleveland Clinic journal of medicine·2026
Same journal

In Reply: Beyond histologic improvement in MASH.

Cleveland Clinic journal of medicine·2026
Same journal

Comfort care: Creating a plan for hospitalized patients and their families.

Cleveland Clinic journal of medicine·2026
Same journal

Localized dead bone, a potential hint to an underlying condition.

Cleveland Clinic journal of medicine·2026
See all related articles

Aminosalicylates are the first-line treatment for mild to moderate ulcerative colitis, with initial doses of 4.8 g daily recommended. Infliximab is an effective option for moderate to severe cases unresponsive to conventional therapies.

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Ulcerative colitis (UC) management guidelines recommend aminosalicylates as initial therapy.
  • Optimal dosing strategies for aminosalicylates in active UC require clarification.

Observation:

  • Current treatment protocols for mild to moderate active UC involve aminosalicylates.
  • Infliximab is an approved biologic for patients with inadequate response to conventional UC treatments.

Findings:

  • Initiating aminosalicylate therapy at 4.8 g daily is more effective than escalating doses.
  • Higher initial dosages of aminosalicylates ensure optimal therapeutic levels for ulcerative colitis.

Implications:

  • Evidence supports starting aminosalicylates at a full therapeutic dose for improved ulcerative colitis outcomes.

Related Experiment Videos

  • Infliximab provides a crucial alternative for refractory moderate to severe ulcerative colitis cases.